Free tool
FAERS Monitor: Zioptan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202514 or its brand name (Zioptan, Tafluprost). Reports on generic versions are filed under their own applications.
Reports
2,936
Serious
1,030
35% of reports
Hospitalization
291
Death reported
330
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ocular hyperaemia467
- eye irritation432
- eye pain299
- eye pruritus232
- drug ineffective215
- death198
- vision blurred178
- headache169
- eye swelling124
- dry eye113
- intraocular pressure increased98
- photophobia87
- lacrimation increased76
- dizziness74
- dyspnoea71
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 17 |
| 2012 | 111 |
| 2013 | 174 |
| 2014 | 99 |
| 2015 | 95 |
| 2016 | 134 |
| 2017 | 211 |
| 2018 | 160 |
| 2019 | 353 |
| 2020 | 484 |
| 2021 | 265 |
| 2022 | 249 |
| 2023 | 207 |
| 2024 | 154 |
| 2025 | 136 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,223 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ocular hyperaemiaSignal | 467 | 71.2 | 65.5 | 32,000 |
| intraocular pressure increasedSignal | 98 | 55.3 | 45.5 | 5,139 |
| eye irritationSignal | 432 | 54.2 | 49.6 | 22,383 |
| eye pruritusSignal | 232 | 49.8 | 44.0 | 10,987 |
| eye painSignal | 299 | 38.2 | 34.3 | 10,755 |
| photophobiaSignal | 87 | 33.3 | 27.0 | 2,682 |
| eye swellingSignal | 124 | 24.0 | 20.2 | 2,700 |
| lacrimation increasedSignal | 76 | 18.1 | 14.5 | 1,207 |
| dry eyeSignal | 113 | 16.3 | 13.6 | 1,602 |
| vision blurredSignal | 178 | 9.3 | 8.1 | 1,317 |
| headache | 169 | 1.9 | 1.7 | 77 |
| death | 198 | 1.6 | 1.4 | 52 |
| drug ineffective | 215 | 1.2 | 1.0 | 5 |
| dizziness | 74 | 1.1 | 0.8 | 0 |
| dyspnoea | 71 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.